What the BTN LiveBIG Minnesota TV commercial - Alzheimers Eye Imaging Test is about.
BTN LiveBIG Minnesota TV Spot, 'Alzheimer's Eye Imaging Test' focuses on highlighting a cutting-edge diagnostic tool developed by researchers at the University of Minnesota's Center for Neuroengineering that could potentially revolutionize Alzheimer's diagnosis.
Through the use of eye imaging technology, researchers have developed a non-invasive test that can identify individuals who are at risk of developing Alzheimer's disease years before symptoms appear. By looking at the retina, which is an extension of the brain, the test can pick up on early changes associated with the disease, allowing for early intervention and treatment.
The TV spot goes on to showcase the power of this technology, featuring interviews with researchers, scientists, and patients. From the emotional story of a caregiver whose mother passed away from the disease to a dedicated researcher who has dedicated her life to finding a cure, the segment highlights the importance of this groundbreaking research.
Thanks to the efforts of these dedicated individuals and the support of the University of Minnesota, this diagnostic tool could revolutionize the way we diagnose and treat Alzheimer's disease, giving hope to millions of people around the world who are affected by this devastating illness.
In summary, the BTN LiveBIG Minnesota TV Spot, 'Alzheimer's Eye Imaging Test' shines a light on the innovative research being done at the University of Minnesota to diagnose and treat Alzheimer's disease, providing hope for future generations.
BTN LiveBIG Minnesota TV commercial - Alzheimers Eye Imaging Test produced for
BTN LiveBIG
was first shown on television on November 1, 2021.
Frequently Asked Questions about btn livebig minnesota tv spot, 'alzheimer's eye imaging test'
The Eye-Brain Connection
The central nervous system and the retina are inextricably linked, and changes in the brain can often be detected in the eyes. Research shows that advanced Alzheimer's disease has been linked to thinning of the central retina and degeneration of the optic nerve.
A new study has found that people with Alzheimer's had fewer blood vessels and less blood flow in the retina (back of their eye). The Alzheimer-linked eye changes were detected by an eye test that uses a scanning technique called Octa (optical coherence tomography angiography).
Some people living with Alzheimer's or other dementia could experience vision changes. This may lead to difficulty with balance or trouble reading. They may also have problems judging distance and determining color or contrast, causing issues with driving.
Retinal changes also correlated with the pathological stage of Alzheimer's disease (called Braak stage) and patients' cognitive status. And they were found even in patients who appeared cognitively normal or very mildly impaired, marking them as a possible early predictor of later cognitive decline.
Computerized tomography (CT)
A CT scan is a type of X-ray that uses radiation to produce images of the brain or other parts of the body. A head CT can show shrinkage of brain regions that may occur in dementia, as well as signs of other possible sources of disease, such as an infection or blood clot.
The five-minute cognitive test (FCT) was designed to capture deficits in five domains of cognitive abilities, including episodic memory, language fluency, time orientation, visuospatial function, and executive function.
Introduction: The five-word test (5WT) is a serial verbal memory test with semantic cuing. It is proposed to rapidly evaluate memory of aging people and has previously shown its sensitivity and its specificity in identifying patients with AD.
Bottom line. You can't tell whether someone has dementia by looking in their eyes. However, vision loss commonly occurs among people with dementia. It's not clear whether vision loss causes dementia or vice versa.
The five-minute cognitive test (FCT) was designed to capture deficits in five domains of cognitive abilities, including episodic memory, language fluency, time orientation, visuospatial function, and executive function.
1 Taking about 10 minutes to complete, the MMSE measures aspects of cognition that include orientation, word recall, attention and calculation, language abilities, and visual construction.
Designed by researchers at Ohio State in 2010, the SAGE test is widely used as a helpful tool to assess cognition and detect early Alzheimer's and dementia. The SAGE test is 12 questions that cover several facets of cognition, including: memory. judgment.
The Mini-Cog test.
A third test, known as the Mini-Cog, takes 2 to 4 minutes to administer and involves asking patients to recall three words after drawing a picture of a clock. If a patient shows no difficulties recalling the words, it is inferred that he or she does not have dementia.
